170 related articles for article (PubMed ID: 23831870)
1. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.
Chen Y; Zhang W; Huang WH; Tan ZR; Wang YC; Huang X; Zhou HH
Eur J Clin Pharmacol; 2013 Nov; 69(11):1933-8. PubMed ID: 23831870
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
3. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.
Hu M; Mak VW; Yin OQ; Chu TT; Tomlinson B
Drug Metab Pharmacokinet; 2013; 28(2):104-8. PubMed ID: 22850760
[TBL] [Abstract][Full Text] [Related]
4. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
Chung JY; Cho JY; Yu KS; Kim JR; Oh DS; Jung HR; Lim KS; Moon KH; Shin SG; Jang IJ
Clin Pharmacol Ther; 2005 Oct; 78(4):342-50. PubMed ID: 16198653
[TBL] [Abstract][Full Text] [Related]
5. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
Wen J; Xiong Y
J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
7. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
8. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.
Zhu J; Song M; Tan HY; Huang LH; Huang ZJ; Liu C; Fu ZM; Huang YY; Tan ZR; Chen XP; Yuan H; Yang GP
Pak J Pharm Sci; 2013 May; 26(3):577-84. PubMed ID: 23625433
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease.
Li Z; Tian S; Wu Z; Xu X; Lei L; Li Y; Wang B; Huang Y
J Ethnopharmacol; 2021 Nov; 280():114469. PubMed ID: 34329714
[TBL] [Abstract][Full Text] [Related]
10. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.
Lee HI; Choi CI; Sa JH; Lee YJ; Bae JW; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):981-5. PubMed ID: 25138679
[TBL] [Abstract][Full Text] [Related]
12. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.
Shirasaka Y; Suzuki K; Shichiri M; Nakanishi T; Tamai I
Drug Metab Pharmacokinet; 2011; 26(2):171-9. PubMed ID: 21206133
[TBL] [Abstract][Full Text] [Related]
13. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers.
Xiang Y; Okochi H; Kozachenko I; Sodhi JK; Frassetto LA; Benet LZ
Clin Pharmacol Ther; 2021 Aug; 110(2):480-485. PubMed ID: 33880760
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Pharmacokinetics of NK-104-NP.
Nakano K; Matoba T; Koga JI; Kashihara Y; Fukae M; Ieiri I; Shiramoto M; Irie S; Kishimoto J; Todaka K; Egashira K
Int Heart J; 2018 Sep; 59(5):1015-1025. PubMed ID: 30158384
[TBL] [Abstract][Full Text] [Related]
16. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
Oh ES; Kim CO; Cho SK; Park MS; Chung JY
Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
18. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of [
Yagi Y; Kimura H; Okuda H; Ono M; Nakamoto Y; Togashi K; Saji H
Nucl Med Biol; 2019; 74-75():25-31. PubMed ID: 31450072
[TBL] [Abstract][Full Text] [Related]
20. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
Fujino H; Saito T; Ogawa S; Kojima J
J Pharm Pharmacol; 2005 Oct; 57(10):1305-11. PubMed ID: 16259759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
